Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index

Rheumatology (United Kingdom)

Volumn 57, Issue 1, 2018, Pages 125-133

  Kalunian, Kenneth C ^a   Urowitz, Murray B ^b   Isenberg, David ^c   Merrill, Joan T ^d   Petri, Michelle ^e   Furie, Richard A ^f   Morgan Cox, Mary Ann ^g   Taha, Rebecca ^g   Watts, Steven ^g   Silk, Maria ^g   Linnik, Matthew D ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Northwell Health   (United States)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

BILAG; Clinical trial; Corticosteroids; Endpoints; Lupus; SLE; SLE Responder Index; SLEDAI; SRI; Systemic lupus erythematosus

Indexed keywords

PLACEBO; PREDNISONE; B CELL ACTIVATING FACTOR; BELIMUMAB; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TNFSF13B PROTEIN, HUMAN;

ALOPECIA; ARTHRITIS; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG DOSE INCREASE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MUCOSAL DISEASE; MUSCULOSKELETAL DISEASE ASSESSMENT; ORGAN SYSTEMS; PATIENT DROPOUT; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RASH; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS RESPONDER INDEX 5; TREATMENT REFUSAL; TREATMENT RESPONSE; ULCER; VASCULAR DISEASE; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, HUMANIZED; B-CELL ACTIVATING FACTOR; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85039052579     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex368     Document Type: Article

References (14)

1. Navarra SV, Guzmán RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31
2. Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-3
3. Zimmer R, Scherbarth HR, Rillo OL, Gomez-Reino JJ, Muller S. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 2013;72:1830-5
4. Furie RA, Leon G, Thomas M et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-tosevere systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis 2015;74:1667-75
5. Merrill JT, van Vollenhoven RF, Buyon JP et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:332-40
6. Isenberg DA, Petri M, Kalunian K et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:323-31
7. Kalunian KC, Merrill JT, Maciuca R et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 2016;75:196-202
8. Khamashta M, Merrill JT, Werth VP et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:1909-16
9. Furie RA, Petri MA, Wallace DJ et al. Novel evidencebased systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51
10. Luijten KM, Tekstra J, Bijlsma JW, Bijl M. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev 2012;11:326-9
11. Isenberg DA, Rahman A, Allen E et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44:902-6
12. Arthritis Advisory Committee meeting briefing document for the 16 November 2010 meeting. BENLYSTA-(belimumab) Treatment of Systemic Lupus Erythematosus. BLA 125370. Figure 9-8. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM233581.pdf
13. Touma Z, Gladman DD, Su J, Ibañez D, Urowitz MB. SLEDAI-2K does not conceal worsening in a particular system when there is overall improvement. J Rheumatol 2015;42:1401-5
14. Manzi S, Sánchez-Guerrero J, Merrill JT et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8